文章核心观点 - 沙尔律师事务所宣布对亿朗科动物保健公司展开调查，因其可能违反证券法 [1] 调查相关情况 - 调查聚焦公司是否发布虚假或误导性声明，以及是否未披露投资者相关信息 [2] - 公司曾宣传其受FDA审查的动物治疗药物，称FDA有完成审查所需数据，技术部分预计在2024年6月底前获批 [2] - 2024年6月27日公司宣布两种药物均无法在6月底获批，且Zenrelia会附带安全警告，当日股价下跌21% [2] 投资者参与方式 - 受损股东可点击指定链接参与，也可联系沙尔律师事务所的Brian Schall免费讨论权益 [3] - 可通过电话310 - 301 - 3335、网站www.schallfirm.com或邮箱[email protected]联系该律所 [3]

文章核心观点 - 艾兰科动物健康公司(Elanco Animal Health Incorporated)开发的两款重要药物Zenrelia和Credelio Quattro正在等待美国食品药品监督管理局(FDA)审批[3] - 2024年6月27日,艾兰科公司宣布FDA预计无法在6月批准这两款药物,并且Zenrelia将带有安全性警示[3] - 由于这一消息,艾兰科股价在2024年6月26日至27日之间下跌超过21%[4] - 律所正在调查艾兰科公司及其高管是否向投资者做出了虚假或误导性陈述[4] 公司概况 - 艾兰科公司是一家开发动物疾病治疗产品的公司[3] - 公司两款重要管线产品Zenrelia和Credelio Quattro正在等待FDA审批[3] 行业概况 - 艾兰科公司开发的Zenrelia和Credelio Quattro是针对犬类皮肤病和寄生虫的治疗药物[3] - 这两款药物的审批进度对艾兰科公司的业务发展至关重要[3][4]

文章核心观点 - 领先的证券法律事务所Bleichmar Fonti & Auld LLP正在调查Elanco Animal Health Incorporated(纽交所代码:ELAN)是否存在违反联邦证券法的行为 [1][2] - Elanco公司正在开发两种重要的动物治疗药物,但FDA审批进度出现延迟,其中一种药物还将带有安全警示标签 [3][4] - 由于上述消息,Elanco股价在2024年6月27日下跌超过21% [5] - 律所正在调查Elanco公司及其高管是否向投资者做出了虚假或误导性陈述 [5] 公司概况 - Elanco公司主要从事动物疾病治疗产品的开发 [3] - 公司正在开发的两种重要药物分别为Zenrelia(治疗犬类皮肤炎)和Credelio Quattro(广谱口服驱虫药) [3] - 公司此前表示FDA已经拥有完成审批所需的全部数据,预计2024年6月底前获批 [4] 监管审批进展 - 但2024年6月27日,Elanco公司宣布FDA将不会在2024年6月批准这两种药物,其中Zenrelia还将带有安全警示标签 [4] - 这一消息导致Elanco股价在2024年6月27日下跌超过21% [5] 调查进展 - 律所正在调查Elanco公司及其高管是否向投资者做出了虚假或误导性陈述 [5] - 投资者如果遭受损失,可以向律所提供相关信息,律所将代表投资者提起诉讼 [6][7] - 律所具有丰富的证券集体诉讼经验,曾在多起重大案件中取得成功 [8]

Additionally, the company has refreshed its Sustainability Accounting Standards Board (SASB) and Taskforce on Climate-related Financial Disclosure (TCFD) reports, as well as its extensive suite of issue briefs covering leading ESG topics and KPIs, to reflect 2023 data. "As we celebrate our 70th anniversary, we're encouraged by the progress our global team has made to continue to raise the bar on our sustainability efforts. Our efforts are embedded across the business to reduce our footprint, increase the ex ...

文章核心观点 - 领先的证券法律事务所Bleichmar Fonti & Auld LLP对Elanco Animal Health Incorporated(纽交所代码:ELAN)进行调查,可能存在违反联邦证券法的行为 [1][2] - Elanco公司正在开发两种重要的动物治疗产品Zenrelia和Credelio Quattro,但FDA在2024年6月未能批准这两种药物,并且Zenrelia将带有安全性警示 [3] - 由于这一消息,Elanco股价在2024年6月27日下跌超过21%,从6月26日的17.97美元/股下跌至14.27美元/股 [4] 公司概况 - Elanco公司主要从事动物疾病治疗产品的开发 [3] - 公司正在开发的两种重要产品分别是Zenrelia(治疗犬类皮肤炎)和Credelio Quattro(广谱口服驱虫药,可治疗跳蚤、蜱和内部寄生虫) [3] 监管审批情况 - Elanco公司表示FDA拥有完成审查所需的所有数据,所有技术部分(包括标签)预计将在2024年6月底前获得批准 [3] - 但2024年6月27日,Elanco公司宣布FDA预计在2024年6月不会批准这两种药物,并且Zenrelia将带有安全性警示 [3] 股价影响 - 由于上述消息,Elanco股价在2024年6月27日下跌超过21%,从6月26日的17.97美元/股下跌至14.27美元/股 [4]

What Can You Do? If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad s ...

Shares of Elanco Animal Health (ELAN) have declined 6.1% since Jul 9, following the completion of the divestiture of its aqua business to Merck Animal Health, a subsidiary of Merck & Co. (MRK) , for approximately $1.3 billion in cash. Although its shares are down, Elanco is focused on the long-term positive strategic move that will enable the company to concentrate on high-value opportunities in pet health and livestock sustainability while enhancing its financial flexibility. The company plans to use the n ...

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral para ...

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain of its executives made materially false and/or misleading statements to investors related to the FDA's approval of its drugs. If you invested in Ela ...

GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elan ...